Longeveron

JHVEPhoto Longeveron (NASDAQ:LGVN) shares climbed in the morning hours Wednesday after the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its lead asset Lomecel-B as a treatment for mild Alzheimer’s. Targeted at regenerative medicines, including cell therapies such as Lomecel-B, the RMAT designation offers regulatory benefits similar toContinue Reading